AI’s Billion Dollar Opportunity in Value-Based Care

The confluence of value-based care (VBC) and artificial intelligence (AI) is creating a significant, yet often misunderstood, market opportunity. As health plans and providers increasingly shift away from fee-for-service models, the demand for AI platforms that can demonstrably reduce costs and improve outcomes under VBC contracts has surged. This article explores the analytical question of where AI health platforms with verifiable evidence can capture share within the $3.17 billion VBC payment market in 2025, which grew to $3.49 billion in 2026 market sizing report on VBC payment market.

The Evidence Imperative: AI Health Platforms in VBC

The value-based care landscape is not merely about adopting new technologies; it’s about proving their financial and clinical efficacy. For AI health platforms, this translates into a critical need for robust, peer-reviewed outcomes data. Without such evidence, participation in VBC arrangements, where payments are tied to performance, becomes untenable. The $3.17 billion VBC payment market in 2025, which grew to $3.49 billion in 2026, alongside a burgeoning healthcare AI market valued at $36.7 billion in 2025 and projected to reach $50.7 billion in 2026, highlights a substantial intersection for AI health platforms that can deliver on VBC-ready evidence. Consider the approaches of companies like Omada Health and Hinge Health. Both operate in chronic disease management, an area ripe for VBC interventions. Omada Health, for instance, focuses on digital care for preventing and managing chronic conditions such as type 2 diabetes and hypertension. Their success in securing VBC contracts with major payers like UnitedHealth Group and Aetna is predicated on their ability to demonstrate measurable improvements in patient health metrics and corresponding cost reductions. Similarly, Hinge Health, specializing in digital musculoskeletal care, has forged partnerships with Cigna, among others, by providing evidence of reduced pain, improved function, and decreased surgical rates. These platforms exemplify how a clear line from intervention to outcome, backed by data, is essential for VBC market penetration. The insights from leaders in the field further underscore this. Hemant Taneja, a prominent venture capitalist, has consistently championed the idea that healthcare innovations must deliver tangible value to gain traction. This aligns perfectly with the VBC ethos, where theoretical benefits give way to demonstrated results. Similarly, Karen DeSalvo, Google’s Chief Health Officer and a former National Coordinator for Health Information Technology, has emphasized the importance of data interoperability and evidence-based decision-making in transforming healthcare. Her perspective reinforces the idea that AI tools, to be truly impactful in VBC, must not only generate data but also integrate seamlessly into existing healthcare workflows and provide actionable, verifiable insights. Another critical player is iRhythm Technologies, known for its Zio XT patch for cardiac arrhythmia detection. While their technology is more diagnostic, its utility in identifying conditions early, potentially averting more costly interventions, positions it favorably within a VBC framework. Payers like UnitedHealth Group and Aetna are increasingly looking for solutions that prevent downstream costs, and accurate, early diagnosis is a cornerstone of this strategy. The ability of iRhythm to provide clear, quantifiable data on arrhythmia detection rates and subsequent management decisions is crucial for its appeal in VBC contracts. The common thread among these successful platforms is their commitment to generating and publishing outcomes data that directly addresses the financial and clinical objectives of VBC.

Regulatory and Industry Frameworks for VBC Evidence

The regulatory environment significantly shapes the requirements for AI health platforms in VBC. CMS VBC Rules, particularly those governing the Medicare Shared Savings Program, establish the foundational principles for accountability and performance measurement. These rules mandate that participating entities, including those leveraging AI, demonstrate improvements in quality of care and reductions in healthcare costs. The Centers for Medicare & Medicaid Innovation (CMMI) further drives this agenda by piloting and scaling innovative payment models that reward value over volume. For AI platforms, this means their outcomes data must align with CMMI’s rigorous evaluation criteria. Industry organizations also play a pivotal role in defining and validating evidence for VBC. AHIP (America’s Health Insurance Plans) represents the payer perspective, advocating for solutions that deliver demonstrable return on investment and improved member health. NCQA (National Committee for Quality Assurance) develops quality measures and accreditation programs that influence how VBC performance is assessed. Similarly, CHCS (Center for Health Care Strategies) focuses on accelerating delivery system reform and promoting value-based payment. AI health platforms seeking to thrive in the VBC market must therefore ensure their outcomes data is not only scientifically sound but also aligns with the quality metrics and reporting standards set forth by these influential bodies. Tools without peer-reviewed outcomes data simply cannot participate in these arrangements, as the risk of unproven efficacy is too high for payers operating under VBC contracts.

Capturing Share in the Value-Based Care AI Market

The path to capturing a significant share of the $3.17 billion VBC payment market in 2025, which grew to $3.49 billion in 2026, for AI health platforms is clear: rigorous, published outcomes evidence. For health plan executives, the decision to integrate an AI solution into a VBC contract hinges on its demonstrated ability to reduce total cost of care, improve population health metrics, and enhance patient experience. For investors, the clarity of reimbursement pathways and the quality of clinical evidence are paramount predictors of commercial success and exit multiples. The success of companies like Omada Health, Hinge Health, and iRhythm Technologies in securing partnerships with major payers such as UnitedHealth Group, Aetna, and Cigna serves as a compelling blueprint. These platforms have understood that in the value-based care era, the product is not just the technology itself, but the measurable, verifiable outcomes it delivers. The ongoing evolution of CMS VBC Rules, including recent proposals emphasizing two-sided financial risk and new models like the ACCESS and LEAD models, and the continued emphasis from organizations like CMMI, AHIP, NCQA, and CHCS will only strengthen the imperative for AI solutions to prove their worth through robust, peer-reviewed data. The market awaits those prepared to meet this evidentiary challenge.